| HS Code | 709176 |
| Productname | BLUE CAP CREAM Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable |
| Productcategory | Pharma Grade API |
| Dosageforms | Tablet, Capsule, Granule, Injection |
| Routesofadministration | Oral, Injectable |
| Physicalform | Cream |
| Grade | Pharma Grade |
As an accredited BLUE CAP CREAM Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
The following application scenarios for Blue Cap Cream pharma grade API cover six production-scale dosage-form routes: immediate-release tablet, hard capsule, oral sachet granule, small-volume aqueous injectable, lyophilized injection, and dry powder injection. No therapeutic indication is assigned; process parameters are compiled from pharmacopoeial general chapters, EU GMP Annex 1:2022, ISO 14644-1:2015, and rotating equipment performance ranges reported in technical bulletins. All values are bracketing ranges that require confirmation against the drug’s registered monograph.
In immediate-release tablet manufacture, the API is processed by high-shear wet granulation when direct compression exhibits segregation because the API fraction has a bulk density below 0.35 g/cm³ or a particle size distribution with D90 above 250 µm. Under high-shear conditions, the active is premixed with microcrystalline cellulose and lactose monohydrate in a 300 L vertical granulator; the binder solution is sprayed at 3–6 m/s impeller tip speed and 1,000–2,000 rpm chopper speed. The granulation end point is controlled by torque or power consumption rather than time because batch-to-batch moisture differences shift wet mass density from 0.45 g/cm³ to 0.61 g/cm³; if the end point is missed by more than 7% torque, tablet weight RSD on a production campaign exceeds 2.0% under USP <905>. The API is layered at 2–25% w/w of the finished core, with povidone K30 (0.5–3.0% w/w), croscarmellose sodium (2.0–5.0% w/w), and magnesium stearate (0.5–1.0% w/w) as lubricant. Granules are dried in a fluid bed at 55–70 °C inlet air to a final moisture of 1.0–2.5% w/w, then milled through a 0.8–1.5 mm screen. Tablet compression is run on a rotary press with B-tooling at 30–80 rpm; precompression force is set at 2–5 kN and main compression at 10–25 kN, producing cores with hardness 50–120 N and friability below 1.0% after 100 drops per Ph. Eur. 2.9.7. Dissolution is evaluated with USP Apparatus II at 50 rpm against the approved Q value; process capability is tracked using ICH Q8(R2) design space limits.
Low-dose capsule filling requires the API to be dispersed at 1–15% w/w in a binary filler of microcrystalline cellulose and lactose monohydrate to keep segregation low enough for dosator pin sampling. The blend is processed in a diffusion blender at 15–25 rpm for 15–25 min; then 0.1–0.5% w/w colloidal silicon dioxide and 0.25–1.0% w/w sodium stearyl fumarate are added as glidant and lubricant. On a dosator-type capsule filling machine with 6.0 mm pins running at 150–250 fills/min, fill weight RSD remains below 1.5% when powder Carr index is below 18 under USP <1174> and room RH is held below 45%. The fill weight is set between 150 and 500 mg into hard gelatin or HPMC capsules; hard gelatin shells are held at 40–45% RH to avoid embrittlement below 35% and softening above 55%. Filled capsules are checked for weight uniformity under USP <905> and Ph. Eur. 2.9.40; dissolution is run at 50 rpm using USP <711> Apparatus II; elemental impurity release is aligned with ICH Q3D. The finished dosage form is a low-dose hard capsule unit.
Fluid bed top-spray granulation is used in oral sachet filling when the API must be dispersed into a free-flowing granule with minimal segregation. The granule size is controlled at D10 ≥ 50 µm, D50 100–250 µm, and D90 ≤ 500 µm; these limits prevent hopper segregation in the form-fill-seal feed frame. The formulation contains API at 0.5–10% w/w, mannitol as the main carrier at 60–90% w/w, a binder at 0–2.0% w/w, a sweetener at 0.1–0.5% w/w, a flavor at 0.1–0.3% w/w, and a lubricant at 0.2–0.5% w/w. Processing is performed in a fluid bed with inlet air 50–70 °C and spray rate 10–30 g/min/kg; final granule moisture is 1.0–2.0% w/w, and sieve analysis is logged every 20 min to detect fines migration. The dried granules are filled into unit-dose sachets on a horizontal form-fill-seal line with a sealing jaw temperature of 140–170 °C; seal strength is measured at 2.0–4.0 N/15 mm per ASTM F88/F88M-23. Uniformity of mass and dosage-unit content is tested under Ph. Eur. 2.9.40 and USP <905>; stability storage follows ICH Q1A(R2) long-term conditions. The final dosage form is a single-dose oral granule sachet for dispersion in water or direct administration.
For small-volume aqueous injectables, the API is dissolved in Water for Injection at 0.1–10.0 mg/mL. The solution is pH-buffered at 4.0–7.0 with citrate or phosphate species, and sodium chloride is used as a tonicity contributor at 0.9% w/v if isotonicity is required. The compounded solution is sparged with nitrogen until dissolved oxygen is below 0.2 mg/L, then filtered through a 0.22 µm PES or PVDF sterilizing-grade filter. Terminal steam sterilization is permitted only when the F0 requirement of 8–15 min at 121 °C does not reduce assay by more than 2.0%; if forced-degradation data show that limit is exceeded, the line is converted to aseptic filtration in an EU GMP Annex 1:2022 Grade A zone. A production-scale vessel with bottom-mounted magnetic drive maintains solution temperature at 2–8 °C during filling to limit oxidative degradation; fill volume is 1–20 mL into USP Type I borosilicate vials or glass ampoules. Subvisible particles are measured by light obscuration under USP <788>, visible particles under USP <790>, and bacterial endotoxins under USP <85>; container closure integrity is verified under USP <1207>. The finished dosage form is a small-volume parenteral solution for injection or infusion after dilution.
| Sterilization route | Control parameter | Limit | Reference |
|---|---|---|---|
| Terminal steam | F0 at coldest solution point | 8–15 min | EU GMP Annex 1:2022 |
| Pre-sterilisation bioburden | Membrane filtration | ≤10 CFU/100 mL | 21 CFR 211.113(b) |
| Filter integrity | Bubble point | Per 0.22 µm filter manufacturer | ISO 13408-2:2018 |
| Subvisible particles | Light obscuration | Limit by fill volume | USP <788> |
When aqueous solution stability data show degradation above 2.0% after 6 months at 25 °C, the API is processed as a lyophilized cake rather than a ready-to-use solution. The pre-lyophilization solution contains API at 1.0–50.0 mg/vial, mannitol as bulking agent at 2.0–5.0% w/v, and sucrose or trehalose as lyoprotectant at 2.0–5.0% w/v; fill volume is 5–10 mL per USP Type I vial. The solution is filled in a Grade A environment and loaded onto a freeze dryer with shelf temperature initially cooled to -40 °C. Primary drying is performed at shelf temperature -25 to -15 °C and chamber pressure 0.1–0.2 mbar; the ramp rate is kept below 0.5 °C/min to avoid collapse, which is observed as lateral shrinkage and haze in commercial lyophilizers. Product temperature is tracked with thermocouples and Pirani gauge data logged at 1 min intervals. Secondary drying is run at 25–35 °C for 6–12 h to reduce moisture below 1.0% w/w under USP <921>. Vials are stoppered under 50–120 mbar nitrogen, and the finished dosage form is a lyophilized powder for reconstitution with Sterile Water for Injection. Published data for this specific API in lyophilized form are limited; the ranges described reflect a formulation shelf-mapping exercise rather than a fixed registration batch.
Aseptic dry powder filling is selected when the API has poor aqueous stability or requires reconstitution immediately before administration. The sterile powder is filled at 50–500 mg per vial as a 100% API fill or as a blend with 2–10% w/w mannitol to reduce static adhesion. Filling is performed in a closed barrier isolator maintaining ISO 14644-1:2015 ISO 5 conditions, with unidirectional airflow at 0.36–0.54 m/s; the isolator is decontaminated with vaporized hydrogen peroxide prior to operation. Vials are washed with Water for Injection at 70 °C and depyrogenated at 250 °C for 30 min. A vacuum drum or dosator auger fill system with 100% checkweighing holds fill accuracy to ±5%; any vial outside this limit is rejected. After filling, vials are flushed with nitrogen to keep headspace oxygen below 1.0% before stoppering. Sterility assurance follows EU GMP Annex 1:2022, and container closure integrity is verified under USP <1207>. The finished dosage form is a dry powder injection for reconstitution in Sterile Water for Injection or Sodium Chloride Injection.
Competitive BLUE CAP CREAM Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618136850665 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618136850665
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
BLUE CAP CREAM Pharma Grade API is a multi-route active pharmaceutical ingredient intended for tablet, capsule, granule, and injectable dosage forms. Despite the product name, the material is a dry powder API, not a topical cream. The grade is supplied for oral and injectable manufacturing, and the specification is designed to support either solid oral or parenteral finished products. The model/grade designation controls the API through particle size distribution, polymorphic form, residual solvents, elemental impurities, water content, bioburden, and bacterial endotoxin limits. Batch release should follow a product-specific specification built under ICH Q6A and ICH Q7. Published data for this specific configuration is limited; the values cited below are compendial or general industrial starting points, not certified batch data.
For oral solid dosage forms, the powder is expected to meet the flow and compressibility requirements of direct compression or the liquid addition requirements of fluid-bed/high-shear wet granulation. For injectables, the same API is expected to meet parenteral-grade bacterial endotoxin and sub-visible particle limits. The key difference from oral-only APIs is the presence of a defined bacterial endotoxin data package and tighter microbial controls. An oral-only API cannot be repurposed for an injectable CTD module without additional qualification under ICH M4Q and regional GMP expectations. Finished-product dissolution testing is typically developed under USP <711> / Ph. Eur. 2.9.3 for tablets and capsules; disintegration is evaluated under USP <701> / Ph. Eur. 2.9.1. Sterile injectable finished products are tested under USP <788> for particulate matter, USP <85> for endotoxin, and USP <71> for sterility.
The specification should include identification, assay, related substances, residual solvents per USP <467> / Ph. Eur. 2.4.24, water content per USP <921> / Ph. Eur. 2.5.12, residue on ignition per USP <281> / Ph. Eur. 2.4.14, and elemental impurities per ICH Q3D using USP <233> / Ph. Eur. 2.4.35. Particle size is determined by laser diffraction per ISO 13320; bulk and tapped densities are measured per USP <616> / Ph. Eur. 2.9.34. For parenteral application, bacterial endotoxin testing per USP <85> / Ph. Eur. 2.6.14 and sterility testing per USP <71> / Ph. Eur. 2.6.1 are necessary. A typical API monograph assay range is 98.0–102.0% on dried basis, but the exact release limit must be justified by batch data.
In tablet and capsule operations, particle size distribution affects blend uniformity, segregation tendency, flow through intermediate bulk containers, compression behaviour, and dissolution from the finished dosage form. A wide span value—defined as (D90 − D10)/D50—can cause fines migration during bin discharge and tablet weight variability. In injectable solution manufacturing, the API is dissolved and filtered; particle size is therefore less critical to the final solution but remains relevant to dissolution rate in the compounding vessel. In suspension injections, particle size is a critical quality attribute because it influences syringeability, resuspendability, and injection-site tolerability. If the API exists in multiple polymorphic forms, X-ray powder diffractometry per Ph. Eur. 2.9.33 and differential scanning calorimetry should be used to confirm the selected form. Storage under ICH Q1A conditions at 25°C/60% RH and 40°C/75% RH should be used to detect polymorph conversion. Milling or micronisation may introduce amorphous content; amorphous fractions can reduce physical stability and alter dissolution. The particle size reduction step must therefore be controlled by laser diffraction, and amorphous content should be monitored by modulated DSC or dynamic vapour sorption if justified.
On a rotary tablet press, direct compression blends with a Carr index above 25% and a flow rate below 10 g/s through a 15 mm orifice have shown weight variability beyond ±3% RSD in production-scale runs. These are generic powder-flow thresholds observed on rotary presses with compression forces between 12 kN and 22 kN; they are not product-specific release values. If moisture content exceeds 2.0% w/w and the powder is hygroscopic, punch sticking and picking may occur. If moisture content falls below 0.5% w/w, tablet hardness can decline because plastic deformation is reduced. These boundaries should be verified for this API by design of experiments.
The following compliance matrix anchors the grade to compendial methods.
| Quality attribute | Reference method | Application boundary |
|---|---|---|
| Identification | FTIR/ATR, HPLC retention time | Batch release for all routes |
| Assay | HPLC per USP <621> / Ph. Eur. 2.2.29 | Release; typical API range 98.0–102.0% |
| Related substances | HPLC-UV, area normalisation | Release and stability; reporting threshold 0.05% |
| Water content | Karl Fischer USP <921> / Ph. Eur. 2.5.12 | Release; oral dry blends and injectable lyophilisates require tighter limits |
| Residual solvents | Headspace GC USP <467> / Ph. Eur. 2.4.24 | Release; Class 2 limits per ICH Q3C |
| Elemental impurities | ICP-MS USP <233> / Ph. Eur. 2.4.35 | Release; ICH Q3D PDE route-dependent |
| Particle size distribution | Laser diffraction ISO 13320 | Release; D10, D50, D90 and span for solid oral and suspension injection |
| Bulk/tapped density | USP <616> / Ph. Eur. 2.9.34 | Release; flow and capsule fill weight |
| Bacterial endotoxins | LAL USP <85> / Ph. Eur. 2.6.14 | Release for injectable and water-sensitive oral products if required |
| Sterility | USP <71> / Ph. Eur. 2.6.1 | Finished injectable release; not typically an API release test |
| Particulate matter | USP <788> / Ph. Eur. 2.9.19 | Finished injectable release; light obscuration and microscopic |
| Dissolution | USP <711> / Ph. Eur. 2.9.3 | Finished tablet/capsule release; method development required |
Direct compression of BLUE CAP CREAM Pharma Grade API is suitable only if the powder's flow and compressibility parameters meet a minimum threshold. If the API is cohesive or has a Carr index above 25%, a wet granulation or roller compaction step is introduced. For wet granulation, binder addition rate, water activity, and drying endpoint are critical process parameters. A fluid bed dryer with inlet air temperature of 60–75°C is a typical starting point for heat-stable APIs, but the product-specific drying curve must be confirmed by loss-on-drying and granule porosity measurement. Over-granulation can reduce granule porosity and extend tablet disintegration time; under-granulation can increase friability. For capsule filling, segregation is a documented risk when the API has a wide span or low bulk density. Tamping pin and dosator capsule machines respond differently to powder bed consolidation; fill weight variability should be monitored at 15 min intervals during start-up and at the end of the run.
Granulation of BLUE CAP CREAM Pharma Grade API for oral solid dosage forms is conducted in a high-shear mixer or a fluidised-bed granulator. Binder addition rate, water activity, and drying endpoint are critical process parameters. If the API is moisture-sensitive, dry granulation by roller compaction is preferred. A roller compactor with a screen size of 1.5–3.0 mm can produce granules with improved flow; however, ribbon density and granule porosity must be established by designed experiments. Excessive compaction can reduce granule porosity and prolong disintegration; insufficient compaction can produce weak granules and high friability.
For injectable products, BLUE CAP CREAM Pharma Grade API is dissolved in Water for Injection or a buffered vehicle and filtered through a sterilising-grade filter with a pore size of 0.22 µm. The API must have low bioburden before filtration; a pre-filtration bioburden alert limit of 10 CFU/100 mL is commonly applied in sterile operations. The finished-product endotoxin limit is calculated from the dose and route. For intravenous products, the K value is 5 EU/kg/h; for intrathecal products, K is 0.2 EU/kg/h. The limit for an API used at 100 mg per container can be derived by dividing the finished-product endotoxin limit by the drug loading. If a product is administered at 1 mg/kg to a 70 kg patient, the finished-product endotoxin limit would be 350 EU/dose; at 100 mg per dose, the API contribution would be 3.5 EU/mg before applying safety factors. These calculations are illustrative and must be repeated with the actual clinical dose and monograph requirements. Published data for this specific configuration is limited.
Particulate matter acceptance for large-volume injectables per USP <788> is ≤25 particles/mL for particles ≥10 µm and ≤3 particles/mL for particles ≥25 µm; for small-volume injectables, the limits are ≤6000 particles/container for ≥10 µm and ≤600 particles/container for ≥25 µm. The API supplier should provide particle burden data from compatibility studies, because insoluble excipients or the API itself may contribute to sub-visible counts after reconstitution.
Where the injectable product is freeze-dried, the API and excipient matrix are lyophilised. The collapse temperature of the formulation must be measured by freeze-drying microscopy; primary drying chamber pressure is often set between 50 mTorr and 200 mTorr with shelf temperature ramped from −40°C to 20°C. These are generic lyophilisation parameters and must be adjusted for the actual formulation. Extractable and leachable assessment is required if the product is stored in a primary container with elastomeric closures; the closure system must meet USP <381> or Ph. Eur. 3.2.9.
Route-specific processing risks and equipment considerations are summarised below.
| Process step | Critical quality attribute | Equipment / range | Risk if uncontrolled |
|---|---|---|---|
| Direct compression | Powder flow, segregation, moisture | Rotary tablet press 12–22 kN compression force, paddle feeder 20–40 rpm | Weight variability, capping, lamination |
| Wet granulation | Granule moisture, endpoint torque, drying rate | High-shear granulator, fluid bed dryer inlet air 60–75°C | Over-granulation, dissolution delay, sticking |
| Capsule filling | Powder plug formation, flow, particle size | Tamping pin or dosator capsule machine | Fill weight variation, segregation, delayed release |
| Injectable solution | Endotoxin, bioburden, sub-visible particles | Sterilising-grade filter 0.22 µm, aseptic filling line | Sterility failure, particulate rejection |
| Sterile filtration | Filter compatibility, API adsorption | PVDF or PES filter capsule | Drug loss on filter, extractables above limits |
Compared with single-route oral APIs, the multi-route designation adds a defined endotoxin and bioburden data package, sub-visible particulate controls, and residual solvent or elemental impurity limits appropriate to parenteral use. The highest route requirement drives the specification. An oral tablet batch may be produced from injectable-grade API, but the reverse is not acceptable without additional qualification. The operational boundary for the powder is environment-dependent: if the API is hygroscopic and relative humidity exceeds 60% RH, pre-drying in a tray dryer or fluid bed dryer may be required before dispensing. Long-term contact with strong acids, bases, or oxidising agents should be avoided unless forced-degradation studies confirm no incompatibility. For formulation development, the powder should be assessed for compatibility with common excipients such as lactose, microcrystalline cellulose, mannitol, and magnesium stearate. Mixtures containing primary amines and reducing sugars may undergo Maillard reaction under warm, moist granulation conditions; if these conditions are present, a dry granulation route is preferred.
